Objectives Acceleration of MR sequences beyond current parallel imaging techniques is possible with the Compressed SENSE technique that has recently become available for 1.5 and 3 Tesla scanners, for nearly all image contrasts and for 2D and 3D sequences. The impact of this technique on examination timing parameters and MR protocols in a clinical setting was investigated in this retrospective study. Material and methods A numerical analysis of the examination timing parameters (scan time, exam time, procedure time, interscan delay time, changeover time, nonscan time) based on the MR protocols of 6 different body regions (brain, knee, lumbar spine, breast, shoulder) using MR log files was performed and the total number of examinations acquired from January to April both in 2017 and 2018 on a 1.5 T MR scanner was registered. Percentages, box plots and unpaired two-sided t tests were obtained for statistical evaluation. Results All examination timing parameters of the six anatomical regions analysed were significantly shortened after implementation of Compressed SENSE. On average, scan times were accelerated by 20.2% (p<0.0001) while procedure times were shortened by 16% (p<0.0001). Considering all anatomical regions and all MR protocols, 27% more examinations were performed over the same 4 month period in 2018 compared to 2017. Conclusion Compressed SENSE allows for a significant acceleration of MR examinations and a considerable increase in the total number of MR examinations is possible.
Objectives: To assess the ability of 3D amide proton transfer weighted (APTw) imaging based on magnetization transfer analysis to discriminate between multiple sclerosis lesions (MSL) and white matter hyperintensities of presumed vascular origin (WMH) and to compare APTw signal intensity of healthy white matter (healthy WM) with APTw signal intensity of MSL and WHM. Materials and Methods: A total of 27 patients (16 female, 11 males, mean age 39.6 years) with multiple sclerosis, 35 patients (17 females, 18 males, mean age 66.6 years) with small vessel disease (SVD) and 20 healthy young volunteers (9 females, 11 males, mean age 29 years) were included in the MSL, the WMH, and the healthy WM group. MSL and WMH were segmented on fluid attenuated inversion recovery (FLAIR) images underlaid onto APTw images. Histogram parameters (mean, median, 10th, 25th, 75th, 90th percentile) were calculated. Mean APTw signal intensity values in healthy WM were defined by "Region of interest" (ROI) measurements. Wilcoxon rank sum tests and receiver operating characteristics (ROC) curve analyses of clustered data were applied. Results: All histogram parameters except the 75 and 90th percentile were significantly different between MSL and WMH (p = 0.018-p = 0.034). MSL presented with higher median values in all parameters. The histogram parameters offered only low diagnostic performance in discriminating between MSL and WMH. The 10th percentile yielded the highest diagnostic performance with an AUC of 0.6245 (95% CI: [0.532, 0.717]). Mean APTw signal intensity values of MSL were significantly higher than mean values of healthy WM (p = 0.005). The mean values of WMH did not differ significantly from the values of healthy WM (p = 0.345). Sartoretti et al. APTw of White Matter Lesions Conclusions: We found significant differences in APTw signal intensity, based on straightforward magnetization transfer analysis, between MSL and WMH and between MSL and healthy WM. Low AUC values from ROC analyses, however, suggest that it may be challenging to determine type of lesion with APTw imaging. More advanced analysis of the APT CEST signal may be helpful for further differentiation of MSL and WMH.
OBJECTIVES Non-Cartesian spiral magnetic resonance (MR) acquisition may enable higher scan speeds, as the spiral traverses the k-space more efficiently per given time than in Cartesian trajectories. Spiral MR imaging can be implemented in time-of-flight (TOF) MR angiography (MRA) sequences. In this study, we tested the performance of five 3-dimensional TOF MRA sequences for intracranial vessel imaging at 1.5 T with qualitative and quantitative image quality metrics based on in vitro and in vivo measurements. Specifically, 3 novel spiral TOF MRA sequences (spiral-TOFs) and a compressed sensing (CS) technology-accelerated TOF MRA sequence (CS 3.5) were compared with a conventional (criterion standard) parallel imaging-accelerated TOF MRA sequence (SENSE). MATERIALS AND METHODS The SENSE sequence (5:08 minutes) was compared with the CS 3.5 sequence (3:06 minutes) and a spiral-TOF (spiral, 1:32 minutes), all with identical resolutions. In addition, 2 further isotropic spiral-TOFs (spiral 0.8, 2:12 minutes; spiral 0.6, 5:22 minutes) with higher resolution were compared with the SENSE. First, vessel tracking experiments were performed in vitro with a dedicated vascular phantom to determine possible differences in the depiction of cross-sectional areas of vessel segments. For the in vitro tests, an additional 3-dimensional proton density-weighted sequence was added for comparison reasons. Second, 3 readers blinded to sequence details assessed qualitative (16 features) and 2 readers assessed quantitative (contrast-to-noise ratio [CNR], contrast ratio [CR], vessel sharpness, and full width at half maximum edge criterion measurements) image quality based on images acquired from scanning 10 healthy volunteers with all 5 TOF sequences. Scores from quantitative image quality analysis were compared with Kruskal-Wallis, analysis of variance, or Welch's analysis of variance, followed by Dunnett's or Dunnett's T3 post hoc tests. Scores from qualitative image quality analysis were compared with exact binomial tests, and the level of interreader agreement was determined with Krippendorff's alpha. RESULTS Concerning the in vitro tests, there were no significant differences between the 5 TOFs and the proton density-weighted sequence in measuring cross-sectional areas of vessel segments (P = 0.904). As for the in vivo tests, the CS 3.5 exhibited equal qualitative image quality as the SENSE, whereas the 3 spiral-TOFs outperformed the SENSE in several categories (P values from 0.002 to 0.031). Specifically, the spiral 0.8 and 0.6 sequences achieved significantly higher scores in 12 categories. Interreader agreement ranged from poor (alpha = -0.013, visualization of internal carotid artery segment C7) to substantial (alpha = 0.737, number of vessels visible, sagittal). As for the quantitative metrics, the CS 3.5 and all 3 spiral-TOFs presented with significantly worse CNR than the SENSE ([mean ± SD] SENSE 37.48 ± 7.13 vs CS 3.5 31.14 ± 5.97 vs spiral 19.77 ± 1.65 vs spiral 0.8 16.18 ± 2.14 vs spiral 0.6 10.37 ± 1.05). The CR values did n...
Objectives Spiral magnetic resonance imaging acquisition may enable improved image quality and higher scan speeds than Cartesian trajectories. We tested the performance of four 3D T1-weighted (T1w) TFE sequences (magnetization-prepared gradient echo magnetic resonance sequence) with isotropic spatial resolution for brain imaging at 1.5 T in a clinical patient cohort based on qualitative and quantitative image quality metrics. Two prototypical spiral TFE sequences (spiral 1.0 and spiral 0.85) and a Cartesian compressed sensing technology accelerated TFE sequence (CS 2.5; acceleration factor of 2.5) were compared with a conventional (reference standard) Cartesian parallel imaging accelerated TFE sequence (SENSE; acceleration factor of 1.8). Materials and Methods The SENSE (5:52 minutes), CS 2.5 (3:17 minutes), and spiral 1.0 (2:16 minutes) sequences all had identical spatial resolutions (1.0 mm3). The spiral 0.85 (3:47 minutes) had a higher spatial resolution (0.85 mm3). The 4 TFE sequences were acquired in 41 patients (20 with and 21 without contrast media). Three readers rated qualitative image quality (12 categories) and selected their preferred sequence for each patient. Two readers performed quantitative analysis whereby 6 metrics were derived: contrast-to-noise ratio for white and gray matter (CNRWM/GM), contrast ratio for gray matter–CSF (CRGM/CSF), and white matter–CSF (CRWM/CSF); and coefficient of variations for gray matter (CVGM), white matter (CVWM), and CSF (CVCSF). Friedman tests with post hoc Nemenyi tests, exact binomial tests, analysis of variance with post hoc Dunnett tests, and Krippendorff alphas were computed. Results Concerning qualitative analysis, the CS 2.5 sequence significantly outperformed the SENSE in 4/1 (with/without contrast) categories, whereas the spiral 1.0 and spiral 0.85 showed significantly improved scores in 10/9and 7/7 categories, respectively (P's < 0.001–0.039). The spiral 1.0 was most frequently selected as the preferred sequence (reader 1, 10/15 times; reader 2, 9/12 times; reader 3, 11/13times [with/without contrast]). Interreader agreement ranged from substantial to almost perfect (alpha = 0.615–0.997). Concerning quantitative analysis, compared with the SENSE, the CS 2.5 had significantly better scores in 2 categories (CVWM, CVCSF) and worse scores in 2 categories (CRGM/CSF, CRWM/CSF), the spiral 1.0 had significantly improved scores in 4 categories (CNRWM/GM, CRGM/CSF, CRWM/CSF, CVWM), and the spiral 0.85 had significantly better scores in 2 categories (CRGM/CSF, CRWM/CSF). Conclusions Spiral T1w TFE sequences may deliver high-quality clinical brain imaging, thus matching the performance of conventional parallel imaging accelerated T1w TFEs. Imaging can be performed at scan times as short as 2:16 minutes per sequence (61.4% scan time reduction compared with SENSE). Optionally, spiral imaging enables increased spatial resolution while maintaining the scan time of a Cartesian-based acquisition schema.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.